Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562796 · ClinicalTrials.gov registry record
Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 149
- Enrollment target
NCT00562796: Completed study, sponsored by Massachusetts General Hospital.
NCT00562796 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 149 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00562796 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 149 participants
- Enrollment target
Study Summary
Obesity is one of the leading causes of cardiovascular-related diseases, including diabetes and heart disease. Obesity, and more specifically abdominal obesity, may cause decreased growth hormone (GH) levels. It is believed that GH deficiency may contribute to increased cardiovascular risk by affecting insulin resistance, inflammatory markers, and blood cholesterol levels. This study will determine the occurrence of GH deficiency in abdominal obesity and whether GH deficiency is associated with increased cardiovascular risk beyond traditional risk factors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
What the finished NCT00562796 record still lists
NCT00562796 is an observational study that tracks outcomes without assigning an intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00562796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00562796 about?
NCT00562796 is a clinical study titled "Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity". Obesity is one of the leading causes of cardiovascular-related diseases, including diabetes and heart disease. Obesity, and more specifically abdominal obesity, may cause decreased growth hormone (GH) levels. It is believed that GH deficiency may contribute to increased cardiovascular risk by affect...
What is the current status of trial NCT00562796?
This trial is currently completed. The enrollment target is 149 participants. The study started on 2007-11. Estimated completion is 2011-05.
Who is sponsoring clinical trial NCT00562796?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia